Novel azobenzene derivatives, methods for their preparation and their use for the therapeutic treatment of ionizing rays
Patent Information
- Application Number
- DE602020041600
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-08
- Filing Date
- 2020-02-07
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2040-02-07
AI Technical Summary
Current therapeutic systems activated by ionizing radiation are limited in depth penetration due to the intrinsic limitations of UV, visible, or near-infrared irradiation, making it challenging to effectively treat deep tissues, and existing compounds require high doses for activation, which is not suitable for clinical applications.
Development of a molecular energy converter (metal chelate) associated with a photosensitive switch (azobenzene group) to create a system that can be activated by highly penetrating light at moderate doses, allowing for deeper tissue penetration and activation of cancer cells using ionizing radiation.
The system induces permeability and death of cancer cells upon activation by ionizing radiation, enabling effective treatment of deep tissues without the need for invasive methods, with the potential for real-time control and modulation of therapeutic actions.
Description
[0001] The present invention relates to the therapeutic treatment of pathologies such as cancer, using compounds which can be activated by ionizing radiation.
[0002] Redox and photosensitive systems have been developed for more than a century and are used to trigger complex actions, such as specific bond cleavage or configuration switching, which can be used to perform the release of active molecules, control protein activity and gene expression, etc. Unfortunately, clinical applications of these sensitive systems are still limited to topical or ophthalmic treatment, due to the current shortage of techniques capable of activating these systems at a depth greater than a few hundred micrometers below the body surface, with the exception of the use of invasive electrodes or optical fibers. Indeed, all photosensitive molecules developed so far are sensitive only to UV, visible or near infrared irradiation, whose penetration into tissues is intrinsically limited.
[0003] Activation of compounds triggered by ionizing radiation has been proposed in particular in WO 2011 / 158189. However, the efficacy is extremely limited, and requires doses too high to be applied clinically.
[0004] CN104447598A describes macrocyclic polyamine derivatives of CA-4 as well as a pharmaceutically acceptable salt or configurational isomers of the macrocyclic polyamine derivatives. The compounds can be used to inhibit the genesis or growth of a tumor. And, a drug composition and application of the compounds in the treatment of tumor diseases.
[0005] It is therefore desirable to provide new compounds that can be activated by irradiation without depth restriction in the target biological tissues. Irradiation by ionizing radiation can be used to effectively reach deep tissues, where the high energy of the radiation will be converted locally to specifically activate redox / photosensitive therapeutic systems.
[0006] According to the invention, a molecular energy converter (metal chelate) is combined with a photosensitive switch (an azobenzene group) to result in a photosensitive system that can be activated by high-penetration light, at moderate doses compatible with clinical applications.
[0007] According to a first object, the present invention therefore relates to a compound of formula (I):
[0008] In which: M represents a metal atom chosen from Ce(III), Pr(III), Nd(III), Sm(III), Eu(III), Gd(III), Tb(III), Dy(III), Ho(III), Er(III), Tm(III), Yb(III), Mg(ll), Ca(II), Mn(II), Fe(II), Fe(III), Cu(II), Zn(II), Ga(III), Y(III), Zr(III), Tc(IV), Tc(VI), Tc (VII), Ru(II), Ru(III), Ru(IV), Pd(II), Ag(I), In(III), Hf (IV), Re(VI), W(II), W(III), W(IV), W(V), W(VI), Os(III), Os(IV), Ir(III), Ir (IV), Pt(II), Au(I), Au (III), TI(III), Zr(IV), Nb(III), Bi(III); n is equal to 1, 2, 3, 4, 5, 6 or 7; V and V', identical or different, are hydrogen atoms or linear or branched C1-C10 alkoxy or alkyl chains, or C1-C10 alkyl chains linked together and comprising one or more heteroatoms chosen from N, O or S, optionally substituted by one or more substituents chosen independently from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups, to form a ring;R1, R1', R2, R2', identical or different, are hydrogen atoms, or linear or branched C1-C10 alkoxy or alkyl chains optionally substituted by one or more substituents independently selected from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups; R3 and R3', identical or different, are hydrogen atoms or linear or branched C1-C10 alkoxy or alkyl chains optionally substituted by one or more substituents independently selected from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups, or R3 and R3' are linked together to form a 5- to 14-membered heterocycle or heteroaryl; m and m', identical or different, are equal to 1 or 2; X, X', X", X‴, Y, Y', Y", Y‴, identical or different, are independently chosen from H; halogen atoms;alkoxy, alkyl or cycloalkyl groups optionally interrupted or substituted by one or more heteroatom(s) or COOH, CONH 2 , COSH, OH, NH 2 , SH groups; aryl or heteroaryl groups of 5 to 12 members optionally substituted by one or more COOH, CONH 2 , COSH groups; COOH or NH 2 groups; Z represents an alkyl group optionally interrupted or substituted by one or more heteroatom(s) or COOH, CONH 2 , COSH, OH, NH 2 , SH groups; a 5 to 12-membered aryl or heteroaryl group optionally substituted by one or more COOH, CONH 2 , COSH groups; or a COOH or NH 2 group; W and W', identical or different, independently represent a CH 2 group; or an aryl or cycloalkyl group; an oxygen or nitrogen atom (secondary or ternary); an amide bond; an ester bond; a thioether bond; U and U', identical or different, represent the CH or NH group, it being understood that the double bond U=U' is in the form; cis Or trans ;T represents a CH 2 group; a -C(=O)NH group; an alkoxy, alkyl or cycloalkyl group optionally interrupted or substituted by one or more heteroatom(s) or COOH, CONH 2 , COSH, OH, NH 2 , SH group; a 5 to 12-membered aryl or heteroaryl group containing one or more heteroatom(s) and / or optionally substituted by one or more groups chosen from COOalkyl, CONHalkyl, COSHalkyl; R represents H, or a linear or branched C1-C18 alkoxy or alkyl chain, optionally substituted by one or more substituents chosen independently from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups; p and q are integers between 0 and 6, in particular between 1 and 6;It being understood that to ensure the neutrality of the molecule, the n cationic charges of M can be neutralized by from 0 to n carboxylate groups (-COOH) optionally substituted on R1, R1', R2, R2', R3, R3', V, V', and / or from 0 to n of the counterions present in solution where appropriate; In isomeric form; cis and / or trans and mixtures thereof Or a pharmaceutically acceptable salt thereof.
[0009] The compounds according to the invention make it possible to induce the permeability and death of cancer cells when activated by ionizing radiation. After introduction of the inactive form ( cis ), irradiation of the target site with ionizing radiation is applied. This radiation induces a conversion of the molecule into its active form (trans)leading to cell permeability and death due to the modification of the lipophilic balance of the molecule. The rays used to activate the molecule penetrate into biological tissues without depth restriction, making the activation technique perfectly suited for clinical applications, unlike traditional photosensitive tools whose activation is limited to irradiations from UV to near infrared (penetration of less than 1 cm of biological tissues).
[0010] The compounds according to the inventions are radiosensitive in that their action is triggered by ionizing radiation. They therefore represent a promising tool for the control and modulation of therapeutic actions in real time.
[0011] As metal M, we can notably cite the metal atoms whose sizes are between Z = 20 and Z = 83, and notably the following metals Fe, Cu, Zn, Ga, Y, Zr, Tc, Ru, Pd, Ag, In, Eu, Gd, Tb, Dy, Ho, Yb, Hf, W, Os, Ir, Pt, Au, Bi.
[0012] In the general formula (I) above, the following embodiments are envisaged, taken separately or in each of their combinations: V and V' are linked together by means of a C1-C9 alkyl chain, comprising 2 nitrogen atoms, optionally substituted by 2 carboxylate groups; and / or V and V' are linked so as to form the chain: and / or Z represents a group -CH(COOH)-; and / or m=m'=1; and / or R2=R3=R2'=R3'=H; and / or R1=R1'=(CH2)COOH; and / or p=q=2; and / or Y=Y'=Y"=Y‴=H; W=W'=O; U=U'=NH.
[0013] According to one embodiment, the compounds of formula (I) obey the general formula (IA):
[0014] In which: M, n, R1, R2, R3, V, m, R1', R2', R3', V', m', p are defined as in formula (I) and X is selected from hydrogen and halogen atoms; R is a linear or branched C1-C12 alkyl group; The N=N double bond is in the form cis Or trans ; It being understood that to ensure the neutrality of the molecule, the n cationic charges of M can be neutralized by from 0 to n carboxylate groups (-COOH) substituted on R1, R1', R2, R2', R3, R3', V, V', and / or from 0 to n of the counterions present in solution where appropriate, Or a pharmaceutically acceptable salt.
[0015] According to one embodiment, the compounds of formula (I) obey the general formula (IB): wherein M, n, p, X and R are defined as above, or a pharmaceutically acceptable salt.
[0016] According to one embodiment, the compounds of formula (I) obey the general formula (IC): in which M, n, X are defined as above, or a pharmaceutically acceptable salt.
[0017] According to one embodiment, in formula (I), (IA) or (IB): X is selected from H and F; and / or R represents a linear C4-C8 alkyl group; p=2; M is a metal selected from Cu, Ga, Y, In, Eu, Gd, Yb, Bi; n=2 or 3.
[0018] In the above and the following: "Alkyl" means an aliphatic hydrocarbon group which may be straight or branched having from about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups have from 1 to about 12 carbon atoms in the chain. Branched means that one or more lower alkyl groups, such as methyl, ethyl or propyl, are attached to a straight alkyl chain.
[0019] “Alkoxy” means an alkyl-O- group, wherein the alkyl group is as described above. Typical examples of alkoxy groups include methoxy, ethoxy,n- propoxy, the i -propoxy, the n -butoxy and heptoxy.
[0020] "Cycloalkyl" means a mono- or multicyclic non-aromatic ring system of about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred ring sizes of the rings of the ring system comprise about 5 to about 6 ring atoms. Exemplary monocyclic cycloalkyls include cyclopentyl, cyclohexyl, cycloheptyl.
[0021] “Carboxy” means an HO(O)C- (carboxylic acid) group.
[0022] “Aryl” means an aromatic monocyclic or multicyclic ring system of about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. Typical examples of aryl groups include phenyl or naphthyl.
[0023] "Heteroaryl" means an aromatic monocyclic or multicyclic ring system of about 5 to about 14 carbon atoms, preferably about 5 to about 10 carbon atoms, wherein one or more of the carbon atoms in the ring system is / are a hetero element(s) other than carbon, e.g., nitrogen, oxygen, or sulfur. Preferred ring sizes of the rings in the ring system comprise about 5 to about 6 ring atoms.Exemplary heteroaryl groups include pyrazinyl, thienyl, isothiazolyl, oxazolyl, pyrazolyl, furazanyl, pyrrolyl, 1,2,4-thiadiazolyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[1,2-a]pyridine, imidazo[2,1-b]thiazolyl, benzofurazanyl, azaindolyl, benzimidazolyl, benzothienyl, thienopyridyl, thienopyrimidinyl, pyrrolopyridyl, imidazopyridyl, benzoazaindole, 1,2,4-triazinyl, benzthiazolyl, furanyl, imidazolyl, indolyl, indolizinyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl.
[0024] "Halogen" means fluorine, chlorine, bromine, or iodine. Fluorine, chlorine, or bromine are preferred, especially fluorine.
[0025] The present invention also relates to the therapeutic use of the compounds according to the invention.
[0026] According to another subject, the present invention relates to pharmaceutical compositions comprising a compound of formula (I) predominantly in the form cis, and at least one pharmaceutically acceptable excipient.
[0027] According to another object, the present invention relates to a compound of formula (I) in the form cis and / or trans for its use in the treatment of cancer.
[0028] The compounds of formula (I) below are activatable by ionizing irradiation, the double bond cis switching in the form trans, cytotoxic.
[0029] Said use therefore comprises the administration of a compound of formula (I) in majority form cis, and the application of irradiations to the target site, so as to form in situ the compound of form trans.
[0030] Said use also includes monitoring of treatment by imaging in vivo by MRI, PET, X-ray or SPECT scan.
[0031] According to one embodiment, said use comprises administering an effective amount of a compound of formula (I), in the form cis, to a patient who needs it.
[0032] According to one embodiment, the administration of said compound of formula (I) can generally be carried out parenterally.
[0033] The ionizing radiations considered generally correspond to the radiations used for radiotherapy treatments. Such actions induced by an external stimulus allow temporal and spatial control and can be adjusted on demand in real time in order to obtain optimal therapeutic efficacy. These include ionizing radiations such as photons (X-rays and γ-rays whose energy can range from 1 keV to 25 MeV), electrons and hadrons (such as protons or carbons from 60 to 300 MeV), and in particular X-rays (1-200 keV), gamma rays (662 keV) and electron beams (4500 keV).
[0034] These radiations make it possible to obtain the desired activation at low doses between 2 and 20 Gy, in particular between 2 and 10 Gy, more particularly between 2 and 5 Gy.
[0035] Since the action of the compounds of the invention is exerted by cell permeability, all cancers can potentially be treated by the compounds of the invention, to the extent that the therapeutic approach is not limited to a specific cell surface signature.These include lung cancer, pancreatic cancer, liver cancer, spleen cancer, small cell lung carcinoma, prostate cancer, rhabdomyosarcoma, stomach cancer, gastrointestinal cancer, colorectal cancer, kidney cancer, breast cancer, ovarian cancer, testicular cancer, thyroid cancer, head and neck cancer, skin cancer, soft tissue sarcoma, bladder carcinoma, bone cancers, myeloma, plasmacytoma, germ cell cancer, uterine cancer, leukemias, lymphomas, neuroblastoma, osteosarcoma, retinoblastoma, central nervous system cancers, Wilms tumors, and especially pancreatic cancer or leukemia.
[0036] According to one embodiment, the use also makes it possible to detect the presence of the compound and possibly its molecular switching. in vivoby MRI thanks to the presence of metal atom(s) in the molecular structure of the compounds of the invention.
[0037] MRI detection of the compounds of the invention allows the localization and monitoring of the therapeutic action of said compounds in a non-invasive manner, thus facilitating the development and monitoring of therapeutic protocols, and thus enabling a theranostic approach.
[0038] According to one embodiment, the compounds of the invention can be administered in combination with one or more anti-cancer agents, such as chemotherapy or immunotherapy such as immune checkpoint inhibitors such as anti-CTLA4, anti-PD-L1 and anti-PD1.
[0039] "Effective amount" means an amount of a compound / composition according to the present invention effective in producing the desired therapeutic effect.
[0040] "Formulations suitable for parenteral administration" means formulations which are in a form suitable for parenteral administration to a patient. Formulations are sterile and include emulsions, suspensions, aqueous and non-aqueous injection solutions, which may contain suspending and thickening agents and antioxidants (after verifying that the potentially radioprotective effect of these does not prevent the desired effect under radiation), buffers, bacteriostats and solutes which render the formulation isotonic, and have a suitably adjusted pH, with the blood of the intended recipient.
[0041] The formulation is preferably administered by injection, including transmuscular, intravenous, intraperitoneal, and subcutaneous injection. For injection, the compounds useful according to the invention may be formulated into liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the compounds may be formulated into solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.
[0042] The choice of vehicle and the content of the active substance in the vehicle are generally determined according to the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice.
[0043] The formulations may be prepared in unit dosage form by any of the methods well known in the art of pharmacy. These methods include the step of bringing into association the active ingredient and the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient and the liquid carriers or the finely fractionated solid carriers or both, and then, if necessary, shaping the product.
[0044] Actual dosage levels of an active ingredient in the compositions of the invention may vary in order to obtain an amount of active ingredient effective to achieve a desired therapeutic response for a particular composition and route of administration. The dosage level chosen therefore depends on the desired therapeutic effect, route of administration, desired duration of treatment and other factors.
[0045] Dosage unit compositions may contain such amounts of such submultiples thereof as may be used to compose the daily dose. It will be understood, however, that the specific dosage level for any particular patient will depend on a variety of factors including body weight, general health, sex, diet, time and method of administration, rates of absorption and excretion, combination with other drugs, and the severity of the condition being treated.
[0046] The amount of each component administered is determined by the treating physicians taking into account the etiology and severity of the disease, the condition and age of the patient, the potency of each component and other factors.
[0047] The formulations may be presented in single-dose or multi-dose containers, e.g., ampoules and vials sealed with elastomeric stoppers, and may be stored in lyophilized form requiring only the addition of a sterile liquid carrier, e.g., water for injections, just before use. Extemporaneously prepared injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the type previously described.
[0048] “Liquid dosage form” means that the dose of the active compound to be administered to the patient is in liquid form, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art, such as water or other solvents, solubilizing agents and emulsifiers, such as, for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (after verifying that the potentially radioprotective effect thereof does not prevent the desired effect under radiation), in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and sorbitan fatty acid esters or mixtures of these substances, and similar.
[0049] "Patient" includes both a human and other mammals.
[0050] "Pharmaceutical composition" means a composition comprising a compound of formula I and at least one component selected from the group consisting of pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or vehicles, such as preservatives, fillers, wetting agents, emulsifying agents, suspending agents, antibacterial agents, antifungal agents, lubricating agents, and dispersing agents, depending on the nature of the mode of administration and the dosage forms. Examples of suspending agents include ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar and tragacanth, or mixtures thereof.Prevention of the action of microorganisms may be provided by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Examples of suitable carriers, diluents, solvents, or vehicles include water, ethanol, polyols, suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
[0051] "Pharmaceutically acceptable" means that it is, within the scope of sound medical judgment, suitable for use in contact with the cells of humans and lower animals without toxicity, irritation, undue allergic response and the like, and is proportionate to a reasonable benefit / risk ratio.
[0052] The term "pharmaceutically acceptable salts" refers to the relatively non-toxic, inorganic and organic acid addition salts and base addition salts of the compounds of the present invention. These salts may be prepared in situduring the final isolation and purification of the compounds. In particular, acid addition salts can be prepared by separately reacting the purified compound in its purified form with an organic or inorganic acid and isolating the salt thus formed. Examples of acid addition salts include the salts described, for example, in S.M. Berge et al., "Pharmaceutical Salts," J. Pharm. Sci., 66: 1-19 (1977). Acid addition salts can also be prepared by separately reacting the purified compound in its acid form with an organic or inorganic base and isolating the salt thus formed. Suitable inorganic base addition salts are prepared from metal bases, which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, and zinc hydroxide.Suitable basic amine addition salts are prepared from amines that have sufficient alkalinity to form a stable salt, and preferably include amines that are often used in medicinal chemistry because of their low toxicity and acceptability for medical use.
[0053] It is to be understood that the present invention covers all suitable combinations of the particular and preferred groupings mentioned herein.
[0054] According to another object, the present invention also relates to the process for preparing the compounds of formula (I), said process comprising: the complexation step of the compound of formula (II):
[0055] In which: R1, R2, R3, V, m, R1', R2', R3', V', m', Z, T, q, p, W, W', X, X', X", X‴, Y, Y', Y", Y‴, R, U, U' are as defined above, In isomer form cis and / or transand mixtures thereof; with a precursor of the metal M, and the possible UV irradiation of the product obtained in order to obtain the isomer cis mostly.
[0056] Complexation with the metallic agent M can generally be carried out in a solvent such as water, at a temperature between room temperature and the reflux temperature of the reaction mixture, for example between 40 and 100°C. Typically, the pH of the solution is maintained between 5 and 7.
[0057] According to one embodiment, the compound of formula (II) corresponds to formula (IIA):
[0058] Wherein R1, R2, R3, V, m, R1', R2', R3', V', m', p, X, R are defined as in formula (I).
[0059] According to one embodiment, the compound of formula (II) corresponds to formula (IIB):
[0060] In which p, X, R are defined as in formula (I).
[0061] According to one embodiment, the compound of formula (II) corresponds to the formula (IIC):
[0062] In which X is defined as in formula (I).
[0063] According to one embodiment, the compound of formula (II) is obtained by coupling a compound of formula (III) and a compound of formula (IV):
[0064] In which: R1, R2, R3, V, m, R1', R2', R3', V', m', Z, T, q, p, W, W', X, X', X", X‴, Y, Y', Y", Y‴, R, U, U' are as defined above; and E is a linear or branched C1-C10 alkoxy or alkyl chain, a cycloalkyl or aryl group, optionally comprising one or more heteroatoms chosen from N, O or S, optionally incorporating or substituted by one or more substituents chosen independently from halogen atoms, and anhydride, carboxy, nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, ester, carboxylic acid or carboxylate groups; it being understood that E contains a nucleophilic substituent such as a hydroxyl, thiol or primary or secondary amine function to effect the coupling on the molecule (III).
[0065] G is a linear or branched C1-C10 alkoxy or alkyl chain, a cycloalkyl or aryl group, optionally comprising one or more heteroatoms selected from N, O or S, optionally substituted by one or more substituents independently selected from halogen atoms, and anhydride, carboxy, nitrile, nitro, thio, amino (primary or secondary), amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups, it being understood that G contains an electrophilic substituent such as an activated carboxylic acid function or an anhydride function to effect the coupling on the molecule (IV).
[0066] The coupling reaction can be carried out in the presence of a base, particularly an organic base such as triethylamine for example. The reaction can be carried out under anhydrous conditions.
[0067] According to one embodiment, the compound of formula (III) corresponds to formula (IIIA):
[0068] In which R1, R2, R3, V, m, R1', R2', R3', V', m', are as defined above.
[0069] According to one embodiment, the compound of formula (III) corresponds to formula (IIIB):
[0070] According to one embodiment, the compound of formula (IV) corresponds to the formula (IVA):
[0071] Wherein p, X, R are as defined in formula (I).
[0072] According to one embodiment, the compound of formula (IV) corresponds to the formula (IVB):
[0073] In which p, W, W', X, X', X", X‴, Y, Y', Y", Y‴, R, U, U' are as defined above. According to one embodiment, the compound of formula (IV) corresponds to the formula (IVC):
[0074] Wherein X is as defined in formula (I).
[0075] Compounds of formula (III) are generally commercial. In particular, the compound of formula (IIIB) is the compound DOTAGA.
[0076] The compounds of formula (IV) can be prepared by application and / or adaptation of the synthetic method described below in the examples.
[0077] Generally, the starting materials and intermediates of the compounds useful according to the invention can be prepared by the application or adaptation of known processes used until now or described in the literature, for example those described by RC Larock in Comprehensive Organic Transformations, VCH publishers, 1989.
[0078] In reactions, it may be necessary to protect reactive functional groups, e.g., hydroxy, amino, imino, thio, carboxy groups, when desired in the final product, to avoid their unwanted participation in the reactions. Traditional protecting groups may be used in accordance with standard practice; for examples, see T.W. Green and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991; J.F.W. McOmie in "Protective Groups in Organic Chemistry" Plenum Press, 1973.
[0079] Unless specifically stated, there are no particular restrictions on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or on the reagents involved. Examples of suitable solvents include: hydrocarbons, which may be aromatic, aliphatic or cycloaliphatic hydrocarbons, such as hexane, cyclohexane, benzene, toluene and xylene; amides, particularly fatty acid amides such as dimethylformamide and ethers, such as diethyl ether and tetrahydrofuran.
[0080] Reactions can take place over a wide range of temperatures, typically between about 0°C and 150°C (preferably between about room temperature and about 100°C). The time required for the reaction can also vary considerably, depending on many factors, including the reaction temperature and the nature of the reactants.
[0081] The compounds thus prepared may be recovered from the reaction mixture by conventional means. For example, the compounds may be recovered by distilling the solvent from the reaction mixture or, if necessary, after distilling the solvent from the mixture from the solution, pouring the remainder into water followed by extraction with a water-immiscible organic solvent, and distilling the solvent from the extract. In addition, the product may, if desired, be further purified by various techniques, such as recrystallization, reprecipitation, or various chromatographic techniques, including column chromatography or preparative thin-layer chromatography.]
[0082] Acid addition salts may be formed with the compounds useful according to the invention in which a base function such as an amino, alkylamino or dialkylamino group is present. Pharmaceutically acceptable, i.e., non-toxic, acid addition salts are preferred. The selected salts are optimally chosen to be compatible with customary pharmaceutical vehicles and suitable for parenteral administration. The acid addition salts of the compounds useful according to this invention may be prepared by reacting the free base with the appropriate acid, by the application or adaptation of known methods.For example, the acid addition salts of the compounds useful according to this invention may be prepared either by dissolving the free base in water or in an aqueous alcoholic solution or suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and the acid in an organic solvent, in which case the salt separates directly or may be obtained by concentration of the solution. The acid addition salts of the compounds useful according to this invention may be regenerated from the salts by the application or adaptation of known methods. For example, the parent compounds useful according to the invention may be regenerated from their acid addition salts by treatment with an alkali, for example aqueous sodium bicarbonate solution or aqueous ammonia solution.
[0083] The compounds useful according to this invention may be regenerated from their base addition salts by the application or adaptation of known methods. For example, the parent compounds useful according to the invention may be regenerated from their base addition salts by treatment with an acid, for example, hydrochloric acid. The base addition salts may be formed when the compound useful according to the invention contains a carboxyl group. The bases which may be used to prepare the base addition salts preferably include those which, when combined with a free acid, produce pharmaceutically acceptable salts, i.e., salts whose cations are not toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not negated by the side effects attributable to the cations.Pharmaceutically acceptable salts, including those derived from alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide and the like. Compounds useful according to the present invention can be readily prepared, or formed during the process of the invention, as solvates (e.g. hydrates).Hydrates of the compounds useful according to the present invention can be readily prepared by recrystallization from an aqueous / organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol. Figures:
[0084] [ Fig 1 ] There figure 1 represents the absorbance spectra of the compounds cis -GdAzo (a) And cis -GdFAzo (d) under gamma irradiation in PBS. PPS1: Photostationary state containing the isomer cis majority. b, e : Histograms representing the molecular activation of the cis -GdAzo and the cis - Azo (control molecule without Gd) (b) or of the cis- GdFAzo and the cis - FAzo (control molecule without Gd) (e) under gamma irradiation in PBS determined by HPLC and calculated by the difference in isomer proportion trans in the middle (n=3). c: Molecular activation of cis-GdAzo and cis - GdFAzo under X-rays, gamma rays and the Linac electron linear accelerator. f : Histogram representing the molecular activation of cis - MAzo (M being the metal indicated on the abscissa) under gamma irradiation in PBS determined by HPLC and calculated by the difference in proportion in isomer trans in the medium (n=3). Gy: Gray (JL -1< ). XR: X-ray irradiation. GR: Gamma ray irradiation. E: Linac electron linear accelerator irradiation. NI: unirradiated. The standard deviations ( standard deviations ) are represented on the graphs. *** P < 0.001 ( Two-wayAnova with Bonferroni post - test ) . [ Fig 2 ] There Figure 2 represents a : Microscopy images of cancer cells (Panc-1, human pancreatic cancer) in the presence of propidium iodide and the inactive compound cis - GdAzo (1, 2) or the active compound trans - GdAzo (3, 4) at a concentration of 500 µM before (1, 3) or 30 min after (2, 4) the introduction of the compounds. Superposition of the images obtained in white light and in fluorescence (propidium iodide in the nuclei appears in red and shows membrane permeabilization). b : Microscopy images of cancer cells (Panc-1) in the presence of propidium iodide and the inactive compound cis- GdAzo at a concentration of 250 µM (1, 2) or 500 µM (3, 4), before (1, 3) or 30 min after (2, 4) irradiation of the medium under gamma radiation (2 Gy). c : Histogram comparing the impact of gamma irradiation (2 Gy) on cell permeabilization (Panc-1) in the presence of propidium iodide and cis - GdAzo (n=3). of: Histograms comparing the impact of gamma radiation irradiation (2 Gy) on the mortality of Gem-resistant cancer cells (CCRF-CEM ARAC-8C, human acute lymphoblastic leukemia) 4 days after treatment in the presence of cis - GdAzo ( d) or in the presence of cis - GdAzo and Gem (0.1 µM) (e) for a period of 1 hour. f : Histogram comparing the impact of gamma irradiation (2 Gy) on the mortality of Gem-resistant cancer cells (CCRF-CEM ARAC-8C) in the presence of Dotarem ®< or Dotarem ®< and Gem (0.1 µM). Gy: Gray (JL -1< ). GR: Gamma irradiation. NI: unirradiated. Standard errors on the mean ( standard error of the mean ) are represented on the graph c and the standard deviations ( standard deviations ) are represented on the graphs df. * P < 0.05, ** P < 0.01, *** P < 0.001 ( Two-way Anova with Bonferroni post-test ) . Examples I. Analytical chromatography methods. Method A
[0085] HPLC (high-performance liquid chromatography) analyses were performed on a 1565 binary HPLC pump (Waters), PAD 2998 reader (Waters), with an Agilent Eclipse XDB-C18 reverse-phase column (length: 250 mm, diameter: 4.6 mm, stationary phase: 5 µm) using a gradient system: water-TFA 0.05% / acetonitrile-TFA 0.05%; 0' (98 / 2), 5' (98 / 2), 25' (0 / 100), 27' (0 / 100), 29' (98 / 2), 35' (98 / 2) at a flow rate of 1 mL.min -1 < (30 µL injected). Data were processed on Empower. Method B
[0086] Liquid chromatography mass spectrometry (LCMS) analyses were performed on an Alliance 2695 system (Waters) with an XBridge C18 reversed-phase column (length: 150 mm, diameter: 2.1 mm, stationary phase: 3.5 µm) using a gradient system: water-FA 0.1% / acetonitrile; 0' (95 / 5), 20' (0 / 100) at a flow rate of 0.25 mL.min -1< (10 µL injected). The mass analyzer was a TOF LCT Premier (Waters). The capillary voltage was 2.8 kV. The cone voltage was 35 V. The source temperature was 120 °C and the desolvation temperature was 280 °C. Data were processed on MassLynx. Method C
[0087] HPLC analyses were performed on a 2525 binary HPLC pump (Waters) coupled to a 515 HPLC pump (Waters), PAD 2996 reader (Waters), with an XBridge C18 reverse-phase column (length: 100 mm, diameter: 3.0 mm, stationary phase: 3.5 µm) using an isocratic water-TFA 0.05% / acetonitrile system at a flow rate of 0.75 mL.min -1 (10 µL injected). The detection wavelength corresponded to the isosbestic point of the compound studied in the mobile phase used. Data were processed on MassLynx. II. Summaries. General
[0088] All reagents were purchased from Sigma-Aldrich or Alfa Aesar with the highest available purity and were used without further purification. DOTAGA anhydride was purchased from CheMatech and was used without further purification. Silica gel (Aldrich 717185 Si 60, 40-63 µm) used for flash chromatographies was purchased from VWR. RP-18 reverse-phase flash chromatographies were performed on a CombiFlash instrument (Biotage). Thin-layer chromatographies were performed using aluminum foils coated with silica gel 60F254 (detection by UV lamp at 254 nm or by ninhydrin). 1< H, 13< C and 19< F NMR spectra were acquired on Bruker 300 MHz or 400 MHz spectrometers at rt. Chemical shifts δ are given in ppm using the solvent as a reference. Coupling constants J are measured in Hz.Coupling profiles are described by the abbreviations d (doublet), t (triplet), and m (multiplet). High-resolution mass spectrometry (HRMS) experiments were performed in H 2 O / methanol 3 / 7 by electrospray ionization in positive mode, unless otherwise stated, using a time-of-flight mass analyzer with a TOF-LCT Premier mass spectrometer (Waters). Analytical chromatographic methods (HPLC and LCMS) are described in a dedicated paragraph. The purity of the synthetic intermediates was determined by 1< H NMR or reversed-phase HPLC. The purity of the final products was determined by reversed-phase HPLC and was confirmed to be > 95%.
[0089] The following compounds have been synthesized: With X=H or F, With M=Cu, Ga, Y, In, Eu, Gd, Yb or Bi, With n=2 or 3 according to the following synthesis scheme Synthesis of 4-hydroxy-4'-butoxyazobenzene (1)
[0090] 4-Butoxyaniline (2.00 mL, 12.0 mmol) and sodium nitrite (0.854 g, 12.0 mmol, 1.0 equiv) were dissolved in a 1:1 EtOH / H 2 O mixture (24 mL) and the medium was cooled to 0 °C. Ice (12 g) was introduced into the medium before the careful addition of cc HCl (2.6 mL). An aqueous solution (6.3 mL) of phenol (1.14 g, 12.0 mmol, 1.0 equiv) and NaOH (0.960 g, 24.0 mmol, 2.0 equiv) previously prepared and cooled to 0 °C was carefully introduced into the medium at 0 °C. The medium was stirred for 20 min at 0 °C and then for 70 min at rt. After adjusting the pH to 1 (cc HCl), the medium was left to stand for 30 min at rt before filtration. The precipitate was washed with water (4x50 mL), solubilized in DCM and the organic phase was dried over MgSO 4 before being concentrated. 4-Hydroxy-4'-butoxyazobenzene 1 (2.76 g, 10.2 mmol, 85%) was isolated as an amorphous black powder.
[0091] 1< H NMR(400 MHz; CDCl 3 ) δ (ppm) : 7,87 (d; J = 8,9 Hz; 2H); 7,82 (d; J = 8,8 Hz; 2H); 6,98 (d; J = 8,9 Hz; 2H); 6,91 (d; J = 8,8 Hz; 2H); 4,03 (t; J = 6,5 Hz; 2H); 1,85 - 1,75 (m; 2H); 1,58 - 1,45 (m; 2H); 0,99 (t; J = 7,4 Hz; 3H).
[0092] 13< C NMR (75 MHz; CDCl 3 ) δ (ppm) : 161,51; 158,38; 146,89; 146,63; 124,81; 124,56; 116,07; 114,92; 68,22; 31,35; 19,33; 13,96.
[0093] HRMS (m / z): calculé pour C 16 H 19 N 2 O 2 , 271,1447 ([M+H] +< ). Trouvé 271,1440.
[0094] R f = 0,36 (SiO 2 ; DCM; UV). Synthesis of 4-( N -( tert -butyloxycarbonyl)-ethoxyamine)-4'-butoxyazobenzene (2)
[0095] Le 4-hydroxy-4'-butoxyazobenzène 1(2.00 g, 7.40 mmol) and K 2 CO 3 (1.53 g, 11.1 mmol, 1.5 equiv) were dissolved in acetone (25 mL). After stirring for 30 min at rt under argon, 2-(Boc-amino)ethyl bromide (4.98 g, 22.2 mmol, 3.0 equiv) was introduced into the medium. After stirring at reflux for 18 h, the medium was filtered while hot, and the precipitate was washed with hot acetone (75 mL). The filtrate was allowed to stand at rt for 30 min before filtration, and the resulting precipitate 1 was washed with cold acetone. The filtrate was allowed to stand at 0 °C for 3 h before filtration. The obtained precipitate 2 was washed with cold acetone and added to precipitate 1. The filtrate was concentrated and purified by flash chromatography on silica (DCM). The 4-( N -( tert -butyloxycarbonyl)-ethoxyamine)-4'-butoxyazobenzene 2 (2.27 g, 5.49 mmol, 74%) was isolated as an amorphous yellow powder (57% by precipitation, 17% by flash chromatography). 1< H NMR(400 MHz; CDCl 3 ) δ (ppm) : 7,86 (2d; J = 8,9 Hz; 4H); 6,99 (2d; J = 8,9 Hz; 4H); 4,10 (t; J = 5,0 Hz; 2H); 4,04 (t; J = 6,5 Hz; 2H); 3,57 (m; 2H); 1,87 - 1,74 (m; 2H); 1,64 - 1,40 (m; 11H); 1,00 (t; J = 7,4 Hz; 3H).
[0096] 13< C NMR (100 MHz; CDCl 3 ) δ (ppm) : 161,46; 160,62; 156,03; 147,51; 147,07; 124,52; 124,48; 114,84; 114,82; 79,79; 68,18; 67,64; 40,27; 31,42; 28,55; 19,38; 13,98.
[0097] HRMS (m / z): calculé pour C 23 H 32 N 3 O 4 ; 414,2393 ([M+H] +< ). Trouvé 414,2396.
[0098] R f = 0,90 (SiO 2 ; DCM / MeOH 98:2; UV). Synthesis of 4-aminoethoxy-4'-butoxyazobenzene (3)
[0099] Le 4-( N -(tert-butyloxycarbonyl)-éthoxyamine)-4'-butoxyazobenzène 2(1.26 g, 3.04 mmol) was dissolved in a 4:1 DCM / TFA mixture (63 mL) and the medium was stirred for 1.5 h at rt. After concentration, diethyl ether (250 mL) was introduced and the precipitate formed was solidified for 1 h before filtration and washing with diethyl ether (4x50 mL). 4-Aminoethoxy-4'-butoxyazobenzene 3 (1.25 g, 2.93 mmol, 96%, TFA salt) was isolated as an amorphous yellow powder.
[0100] 1< H NMR (400 MHz; MeOD) δ (ppm): 7.88 (d; J = 8.9 Hz; 2H); 7.85 (d; J = 8.9 Hz; 2H); 7.15 (d; J = 8.9 Hz; 2H); 7.04 (d; J = 8.9 Hz; 2H); 4.32 (t; J = 4.4 Hz; 2H); 4.06 (t; J = 6.4 Hz; 2H); 3.41 (t; J = 4.4Hz; 2H); 1.86 - 1.73 (m; 2H); 1.60 - 1.46 (m; 2H); 1.00 (t; J = 7.4 Hz; 3H).
[0101] 13< C NMR(75 MHz; MeOD) δ (ppm): 163.03; 161.34; 148.97; 148.10; 125.42; 125.30; 115.99; 115.80; 69.12; 65.59; 40.24; 32.43; 20.28; 14.16.
[0102] HRMS (m / z): calculated for C 18 H 24 N 3 O 2 , 314.1869 ([M+H] +< ). Found 314.1864.
[0103] HPLC (method A); t R 17.92 min (cis)-20.35 min (trans).
[0104] R f = 0.70 (SiO 2; DCM / MeOH 95:5; UV or ninhydrin). Synthesis of 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (Azo)
[0105] 4-Aminoethoxy-4'-butoxyazobenzene 3 (259 mg, 0.606 mmol, TFA salt) was dissolved in anhydrous DMF (4.3 mL). After introduction of triethylamine (253 µL, 1.81 mmol, 3.0 equiv), the medium was stirred for 5 min at rt under argon. DOTAGA anhydride (278 mg, 0.606 mmol, 1.0 equiv) was then introduced and the medium was stirred for 21 h at 70 °C under argon. After concentration, diethyl ether (100 mL) was introduced and the precipitate formed was solidified for 30 min before filtration and washing with diethyl ether (2x50 mL). The crude was purified by reverse-phase flash chromatography (RP-18, Biotage, gradient H 2 O 0.05% FA / CH 3 CN 0.05% FA 1:0 to 2:8). 4-(N-(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene Azo (294 mg, 0.381 mmol, 63%) was isolated by lyophilization as an electrostatic yellow powder.
[0106] HRMS(m / z): calculated for C 37 H 54 N 7 O 11 ; 772.3881 ([M+H] +< ). Found 772.3883.
[0107] LCMS (method B); t R 12.357 min (cis)-14.437 min (trans). Synthesis of 2,6-difluoro-4-hydroxy-2',6'-difluoro-4'-butoxyazobenzene (4)
[0108] 2,6-Difluoro-4-butoxyaniline (2.20 g, 10.9 mmol) and sodium nitrite (0.755 g, 10.9 mmol, 1.0 equiv) were dissolved in a 1:1 EtOH / H 2 O mixture (22 mL) and the medium was cooled to 0 °C. Ice (11 g) was introduced into the medium before the careful addition of cc HCl (2.37 mL). An aqueous solution (5.7 mL) of 3,5-difluorophenol (1.42 g, 10.9 mmol, 1.0 equiv) and NaOH (0.876 g, 21.9 mmol, 2.0 equiv) previously prepared and cooled to 0 °C was carefully introduced into the medium at 0 °C. The medium was stirred for 20 min at 0 °C and then for 70 min at rt. After adjusting the pH to 1 (cc HCl), the medium was left to stand for 30 min at rt before filtration. The precipitate was washed with water (4x50 mL), solubilized in DCM and the organic phase was dried over MgSO 4 before being concentrated. The residue (black viscous liquid) was concentrated under a vacuum ramp (3.15 g) and was used without further purification in the next step.
[0109] 1< H NMR (400 MHz; DMSO) δ (ppm) : 6,93 (d; J HF = 11,4 Hz; 2H); 6,64 (d; J HF = 11,4 Hz; 2H); 4,09 (t; J = 6,5 Hz; 2H); 1,77 - 1,66 (m; 2H); 1,49 - 1,38 (m; 2H); 0,94 (t; J = 7,4 Hz; 3H).
[0110] 13< C NMR (101 MHz; DMSO) δ (ppm) : 161,40 (t; J CF = 14,8 Hz); 161,11 (t; J CF = 14,8 Hz); 157,69 (dd; J CF = 39,1; 7,7 Hz); 155,13 (dd; J CF = 38,2; 7,8 Hz); 125,00 (t; J CF = 10,2 Hz); 124,05 (t; J CF = 10,3 Hz); 100,26 (dd; J CF = 22,6; 2,0 Hz); 99,68 (dd; J CF = 24,2; 2,1 Hz); 68,74 (s); 30,31 (s); 18,55 (s); 13,58 (s).
[0111] NMR 19< F (376 MHz; DMSO; découplé) δ (ppm) : -118,99; -119,27.
[0112] NMR 19< F (376 MHz; DMSO) δ (ppm) :-118,99 (d; J FH = 12,1 Hz); -119,27 (d; J FH = 12,0 Hz).
[0113] HRMS(m / z): calculated for C 16 H 15 F 4 N 2 O 2 , 343.1070 ([M+H] +< ). Found 343.1060.
[0114] R f = 0.20 (SiO 2 ; cyclohexane / ethyl acetate 9:1; UV). Synthesis of 2,6-difluoro-4-( N -( tert -butyloxycarbonyl)-ethoxyamine)-2',6'-difluoro-4'-butoxyazobenzene (5)
[0115] 2,6-difluoro-4-hydroxy-2',6'-difluoro-4'-butoxyazobenzene 4 (2.18 g of crude, 6.37 mmol considered) and K 2 CO 3 (1.32 g, 9.57 mmol, 1.5 equiv) were dissolved in acetone (22 mL). After 30 min of stirring at rt under argon, 2-(Boc-amino)ethyl bromide (4.29 g, 19.1 mmol, 3.0 equiv) was introduced into the medium. After stirring at reflux for 18 h, the medium was concentrated and purified by flash chromatography on silica (cyclohexane / ethyl acetate, gradient 1 / 0 to 7 / 3). 2,6-Difluoro-4-( N -( tert- butyloxycarbonyl)-ethoxyamine)-2',6'-difluoro-4'-butoxyazobenzene 5 (624 mg, 1.28 mmol, 17% over 2 steps) was isolated as an amorphous yellow powder.
[0116] 1< H NMR(400 MHz; DMSO) δ (ppm) : 7,04 (s; 1H); 6,95 (d; J HF = 11,8 Hz; 4H); 4,10 (m; 4H); 3,34 - 3,26 (m; 2H); 1,75 - 1,67 (m; 2H); 1,49-1,39 (m; 2H); 1,38 (s; 9H); 0,94 (t; J = 7,4 Hz; 3H).
[0117] 13< C NMR (101 MHz; DMSO) δ (ppm) : 161,53 (t; J cF = 14,3 Hz); 161,16 (t; J cF = 14,2 Hz); 157,59 (t; J CF = 7,9 Hz); 155,64 (s); 155,03 (t; J CF = 7,7 Hz); 125,09 (t; J CF = 8,3 Hz); 124,90 (t; J cF = 8,3 Hz); 99,90 (dd; J CF = 11,3; 1,7 Hz); 99,67 (dd; J CF = 11,3; 1,7 Hz); 77,86 (s); 68,80 (s); 67,87 (s); 38,71 (s); 30,29 (s); 28,17 (s); 18,53 (s); 13,57 (s).
[0118] NMR 19< F (376 MHz; DMSO; découplé) δ (ppm) : -118,79; -118,85.
[0119] NMR 19< F (376 MHz; DMSO) δ (ppm) : -118,79 (d; J FH = 12,0 Hz); -118,85 (d; J FH = 11,9 Hz).
[0120] HRMS(m / z): calculated for C 23 H 28 F 4 N 3 O 4 ; 486.2016 ([M+H] +< ). Found 486.2015.
[0121] R f = 0.30 (SiO 2 ; cyclohexane / ethyl acetate 8:2; UV). Synthesis of 2,6-difluoro-4-aminoethoxy-2',6'-difluoro-4'-butoxyazobenzene (6)
[0122] 2,6-Difluoro-4-( N -( tert- butyloxycarbonyl)-ethoxyamine)-2',6'-difluoro-4'-butoxyazobenzene 5 (879 mg, 1.81 mmol) was dissolved in a 4:1 DCM / TFA mixture (37 mL) and the medium was stirred for 1.5 h at rt. After concentration, diethyl ether (200 mL) was introduced and the precipitate 1 formed was solidified for 1 h before filtration and washing with diethyl ether (4x100 mL). The filtrate was concentrated and a viscous precipitate 2 was formed in n-hexane (200 mL), filtered and washed with n-hexane (3x200 mL). Precipitates 1 and 2 were dried under a vacuum ramp. 2,6-Difluoro-4-aminoethoxy-2',6'-difluoro-4'-butoxyazobenzene 6(858 mg, 1.72 mmol, 95%, TFA salt) was isolated as a yellow amorphous powder (precipitate 1.70%) and a yellow oil (precipitate 2.25%).
[0123] 1< H NMR (400 MHz; DMSO) δ (ppm): 7.98 (s; 3H); 7.00 (d; J HF = 11.3 Hz; 2H); 6.96 (d; J H- F = 11.8 Hz; 2H); 4.30 (t; J = 5.0 Hz; 2H); 4.11 (t; J = 6.5 Hz; 2H); 3.26 (t; J = 5.0 Hz; 2H); 1.80 - 1.63 (m; 2H); 1.53 - 1.33 (m; 2H); 0.94 (t; J = 7.4 Hz; 3H).
[0124] 13< C NMR (101 MHz; DMSO) δ (ppm): 161.76 (t; J CF = 14.4 Hz); 160.27 (t; J CF = 14.0 Hz); 157.57 (dd; J CF = 25.8; 7.6 Hz); 155.00 (dd; J CF = 25.9; 7.4Hz); 125.57(s); 124.86(s); 100.07 (dd; J CF = 24.7; 2.7 Hz); 99.80 (dd; J CF = 24.7; 2.5Hz); 68.85(s); 65.82(s); 38.06(s); 30.29(s); 18.54(s); 13.57(s).
[0125] NMR 19< F(376 MHz; DMSO; decoupled) δ (ppm): -73.46; -118.60; -118.74.
[0126] NMR 19< F (376 MHz; DMSO) δ (ppm): -73.46 (s); -118.60 (d; J FH = 11.9 Hz); -118.73 (d; J FH = 11.8 Hz).
[0127] HRMS (m / z): calculated for C 18 H 20 F 4 N 3 O 2 ; 386.1492 ([M+H] +< ). Found 386.1491.
[0128] R f = 0.33 (SiO 2; DCM / MeOH 95:5; UV or ninhydrin). Synthesis of 2,6-difluoro-4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-2',6'-difluoro-4'-butoxyazobenzene (FAzo)
[0129] 2,6-Difluoro-4-aminoethoxy-2',6'-difluoro-4'-butoxyazobenzene 6 (267 mg, 0.535 mmol, TFA salt) was dissolved in anhydrous DMF (3.8 mL). After introduction of triethylamine (223 µL, 1.60 mmol, 3.0 equiv), the medium was stirred for 5 min at rt under argon. DOTAGA anhydride (245 mg, 0.533 mmol, 1.0 equiv) was then introduced and the medium was stirred for 21 h at 70 °C under argon. After concentration, diethyl ether (100 mL) was introduced and the precipitate formed was solidified for 30 min before filtration and washing with diethyl ether (2x50 mL). The crude was purified by reverse-phase flash chromatography (RP-18, Biotage, gradient H 2 O 0.05% FA / CH 3 CN 0.05% FA 1:0 to 2:8). 2,6-Difluoro-4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-2',6'-difluoro-4'-butoxyazobenzene FAzo (92.1 mg, 0.109 mmol, 20%) was isolated by lyophilization as an electrostatic yellow powder.
[0130] HRMS (m / z): calculated for C 37 H 50 F 4 N 7 O 11 ; 844.3504 ([M+H] +< ). Found 844.3495.
[0131] LCMS (method B); t R 14.107 min ( cis )-14,894 min ( trans ). General protocol for the complexation of Azo and FAzo
[0132] Azo Or FAzo and the metal reagent were dissolved in H2O (26 mM). After adjusting the pH to 5.5, the medium was stirred for 17 h at 50 °C, ensuring that the pH remained within the range 5.5-6.0. The pH was then adjusted to 6.5 before concentrating the medium by lyophilization and then purifying it by reverse-phase flash chromatography (RP-18, Biotage, H2O / CH3CN gradient 1:0 to 0:1). The final product was isolated by lyophilization as an electrostatic powder. [Table 1]
[0133] Table 1. Experimental conditions of complexation reactions. Metal Starting product Reaction scale (µmol starting product) Reagent type Quantity of reagent (equiv) Yield (%) Color of the final product Cu Azo 104 Cu(OAc) 2 1,05 60 Green Ga Azo 78,0 GaNO 3 2,05 82 YELLOW Y Azo 90,0 Y Cl 3- 6H 2 O 1,05 31 YELLOW In Azo 80,0 InCl 3- 4H 2 O 1,05 27 YELLOW I Azo 130 EuCl 3- 6H 2 O 1,05 39 YELLOW Gd Azo 259 GdCl 3- 6H 2 O 1,05 88 YELLOW Gd FAzo 142 GdCl 3- 6H 2 O 1,05 97 YELLOW Yb Azo 110 YbCl 3- 6H 2 O 1,05 21 YELLOW Bi Azo 104 BiCl 3 * 1,05 73 YELLOW *: 250 mM in 6N HCL. Copper 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (CuAzo)
[0134] HRMS (m / z): calculated for C 37 H 51 N 7 NaO 11 Cu; 855.2840 ([M+Na] +< ). Found 855.2854. LCMS (method B); t R 13.550 min (cis)-15.934 min ( trans ). Gallium 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (GaAzo)
[0135] HRMS (m / z): calculated for C 37 H 51 N 7 O 11 Ga; 838.2902 ([M+H] +< ). Found 838.2906.
[0136] LCMS (method B); t R 12.840 min (cis)-15.072 min (trans). Yttrium 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (YAzo)
[0137] HRMS (m / z): calculated for C 37 H 49 N 7 Na 2 O 11 Y; 902.2344 ([M-H+2Na] +< ). Found 902.2349. LCMS (method B); t R 15.957 min ( cis )-19,660 min (trans). Indium 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (InAzo)
[0138] HRMS (m / z): calculated for C 37 H 49 N 7 Na 2 O 11 In; 928.2324 ([M-H+2Na] +< ). Found 928.2319. LCMS (method B); t R 15.451 min (cis)-18.899 min (trans). Europium 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (EuAzo)
[0139] HRMS (m / z) (negative mode): calculated for C 37 H 49 N 7 O 11 Eu; 920.2702 ([MH]). Found 920.2694.
[0140] LCMS (method B); t R 13.419 min ( cis )-16,718 min (trans). Gadolinium 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (GdAzo)
[0141] HRMS (m / z): calculated for C 37 H 49 N 7 Na 2 O 11 Gd; 971.2527 ([M-H+2Na] +< ). Found 971.2529.
[0142] LCMS (method B); t R 15.956 min ( cis )-19,633 min (trans). Gadolinium 2,6-difluoro-4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acid
[0143] acetic-10-glutaryl)-ethoxyamine)-2',6'-difluoro-4'-butoxyazobenzene (GdFAzo)
[0144] HRMS (m / z): calculated for C 37 H 45 F 4 N 7 Na 2 O 11 Gd; 1043.2150 ([M-H+2Na] +< ). Found 1043.2158.
[0145] LCMS (method B); t R 18,900 min (cis)-20,524 min (trans). Ytterbium 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (YbAzo)
[0146] HRMS (m / z): calculated for C 37 H 49 N 7 Na 2 O 11 Yb; 987.2674 ([M-H+2Na] +< ). Found 987.2683.
[0147] LCMS (method B); t R 16.112 min (cis)-19.968 min (trans). Bismuth 4-( N -(1,4,7,10-tetraazacyclododecane-1,4,7-tri-acetic acid-10-glutaryl)-ethoxyamine)-4'-butoxyazobenzene (BiAzo)
[0148] HRMS (m / z): calculated for C 37 H 49 N 7 Na 2 O 11 Bi; 1022.3089 ([M-H+2Na] +< ). Found 1022.3093.
[0149] LCMS (method B); t R 14.235 min (cis)-19.055 min (trans). III. Ionizing and cell irradiation experiments General
[0150] Buffer media such as phosphate buffered saline (PBS), Dulbecco's Modified Eagle Medium-high glucose (DMEM), Roswell Park Memorial Institute medium (RPMI), penicillin, streptomycin, and trypan blue solution (0.4%) were purchased from Sigma Aldrich (France). Fetal bovine serum (FBS) was purchased from Gibco (France), propidium iodide (PI) was purchased from Thermo Fisher Scientific (France), and gemcitabine hydrochloride (Gem) was purchased from Sequoia Research Products (UK). Cell lines
[0151] Human pancreatic cancer (PANC-1) and human acute lymphoblastic leukemia (CCRF-CEM) cells were purchased from ATCC (US) and maintained as recommended by the supplier. Gem-resistant human acute lymphoblastic leukemia (CCRF-CEM ARAC 8C, hENT receptor-1 not expressed) cells were kindly provided by Dr. Buddy Ullmann (Oregon Health Sciences University). Briefly, PANC-1 cells were maintained in DMEM buffer supplemented with 10% (v / v) heat-inactivated FBS. CCRF-CEM and CCRF-CEM ARAC-8C cells were maintained in RPMI buffer supplemented with 10% (v / v) heat-inactivated FBS. All cell media were supplemented with penicillin (50 U.mL -1< ) and streptomycin (0.05 mg.mL -1< ). Cells were maintained in a humidified atmosphere at 37 °C with 5% CO2. Cells were used before reaching the eighteenth passage and were harvested at 70-80% confluence. Sources of ionizing radiation
[0152] UV irradiation. UV irradiation to induce isomerization of the isomer trans in isomer cis was carried out in a CN-15.LC chamber (Vilber Lourmat) equipped with two 15W tubes (365 nm) which provided an irradiance of 0.817 mW.cm -2< at the irradiation position (determined by a Cole-Parmer VLX-3W microprocessor-controlled radiometer calibrated for 365 nm, Vilber Lourmat).
[0153] X-ray irradiation. X-ray irradiation was performed with an X-ray generator (Xrad 320 Dx) providing photons at an average energy of 80 keV (range 0-200 keV) at a dose rate of approximately 1 Gy / min (operating at 200 kV, 20 mA). Irradiation doses are expressed in Gray.
[0154] Gamma ray irradiation.Gamma-ray irradiation was performed with a Cesium-137 source (IBL 637) providing 662 keV photons at a dose rate of approximately 1 Gy / min. Irradiation doses are expressed in Gray (1 Gy=1 J / L). Electron beam irradiation. Electron beam irradiation was performed with a linear electron accelerator (Linac, Kinetron) delivering electrons at an energy of 4.5 MeV at a dose rate of approximately 4 Gy / min. Irradiation doses are expressed in Gray. Quantification of ionizing radiation-induced isomerization by absorbance spectrophotometry and HPLC (Figure 1)
[0155] Gd-containing compounds (GdAzo or GdFAzo) and control compounds (Azo or FAzo) (50 µM, 200 µL, PBS) were introduced into two 96-well microplates (10 wells for each compound). Both microplates were first irradiated under UV (365 nm, 0.817 mW.cm -2 < , 5 min). One microplate (plate 1) was then kept in the dark and used as a non-irradiated control while the second (plate 2) was irradiated with an increment of ionizing irradiation doses (2 Gy, 3 Gy, 5 Gy and 10 Gy). After each irradiation, absorbance spectrophotometry and HPLC injection analyses (method C) were performed on the non-irradiated (plate 1) and irradiated (plate 2) compounds. A 26 min time lag between UV irradiation of plates 1 and 2 was performed to allow analysis of non-irradiated control compounds (plate 1) at the same time as compounds irradiated by ionizing radiation (plate 2) after UV irradiation.The entire experiment was performed in 4.6 h. Absorbance spectra were plotted by triplicate averaging. The relative amount of each isomer was obtained by HPLC (detection at the wavelength of the isosbestic point under the elution conditions) and the molecular activation (%) was determined by the difference in the proportion of isomers. trans in the environment (3 independent experiments). Confocal microscopy without ionizing radiation (Figure 2a)
[0156] The cells (PANC-1) were transferred into an imaging plate (8-well ibiTreat micro-slide purchased from Ibidi, Germany) 24 h before the start of the experiment, and were maintained in the culture medium (33,000 cells in 200 µL / well) under a humid atmosphere at 37 °C with 5% CO2. Just before the experiment, the cell medium was replaced with culture medium without FBS and without phenol red (100 µL) and then PI (5 µL, final concentration 1 µM) was added into the medium. 15 min after the addition of PI, a first series of images was acquired. Then the cis-GdAzo or trans-GdAzo compound (100 µL, final concentration 0 µM, 250 µM or 500 µM) was introduced into the cell medium. The imaging plate was then kept in the dark and images were acquired every 5 min for 1 h. The cis-GdAzo compound was obtained by UV irradiation (365 nm, 0.817 mW.cm -2< , 30 min) of the trans-GdAzo compound (105 µL, 500 µM or 1 mM, cis-GdAzo > 85%) in a 96-well microplate. Cells were observed with a Leica TCS SP8 gated-STED inverted microscope (Leica, Germany) using a HC PL Fluotar CS2 10x / 0.30 sec objective. The instrument was equipped with a white-light laser (excitation wavelength 538 nm). Red fluorescence emission was collected over a bandwidth of 560-650 nm, and transmission images were obtained with the same beamline and a PMT-trans detector. The pinhole was set to 1.0 Airy (73.19 µm diameter). 16-bit digital images were obtained with Leica SP8 LAS X software (version 2.0.1, Leica, Germany). Confocal microscopy in the presence of ionizing radiation (Figures 2b-c)
[0157] The cells (PANC-1) were transferred into an imaging plate (Lab-Tek chamber slide system, glass, 8 well purchased from Thermo Fisher Scientific, France) 24 h before the start of the experiment, and were maintained in the culture medium (10,000 cells in 200 µL / well) under a humid atmosphere at 37 °C with 5% CO2. Just before the experiment, the cell medium was replaced with PBS (100 µL) and PI (5 µL, final concentration 1 µM) was added into the medium. 15 min after the addition of PI, cis-GdAzo (100 µL, final concentration 0 µM, 250 µM, 500 µM or 850 µM) was introduced into the cell medium. A first series of images was acquired at this stage, then the imaging plate was irradiated (gamma-rays, 2 Gy). The imaging plate was then kept in the dark at 37 °C (stage heater) and images were acquired every 5 min for 30 min, then every 10 min for 90 min. A similar procedure was used for the control experiment without irradiation except that the imaging plate was not irradiated with gamma-rays. The cis-GdAzo compound was obtained by UV irradiation (365 nm, 0.817 mW.cm -2 < , 30 min) of the trans-GdAzo compound (105 µL, 500 µM, 1 mM or 1.7 mM, cis-GdAzo > 85%) in a 96-well microplate. The cells were observed with a Nikon inverted microscope (Nikon Instruments Inc., Tokyo, Japan) using a 10x sec, NA 0.4 objective lens and equipped with a Yokogawa CSU-X1 head.The instrument was equipped with a 561 nm laser diode as the excitation wavelength. Red fluorescence emission was collected over a bandwidth of 598-672 nm and transmission images were obtained with a white diode. The pinhole was set at 50 µm and the magnification lens at 1.2. Images were recorded by an e-Volve s-CMOS camera (Photometrics). Four images were recorded per well and two wells were used for each cis-GdAzo concentration. 16-bit digital image analyses were performed on ImageJ software (version 1.50i completed with the Adjustable Watershed plugin). The number of cells on the images acquired before irradiation was determined manually and the number of fluorescent cells on the images acquired before and after irradiation was calculated automatically using a script coded on ImageJ.Cell permeabilization was determined by the difference in the proportion of fluorescent cells before and 30 min after gamma-ray irradiation (3 independent experiments). Therapeutic effect under ionizing radiation (Figures 2d-f)
[0158] Just before the experiment, cells (CCRF-CEM ARAC-8C) were dispersed in PBS and transferred to a 48-well microplate (TPP cell culture microplates purchased from Thermo Fisher Scientific, France) (40,000 cells in 80 µL / well). Gem (20 µL, final concentration 0.1 µM) or PBS (20 µL) and cis-GdAzo compound (100 µL, final concentration 0 µM, 250 µM, 500 µM or 850 µM) were added just before gamma-ray irradiation of the medium (2 Gy). The medium was kept in the dark and a humid atmosphere at 37 °C with 5% CO2 for 1 h. Then, culture medium (600 µL) was added to each well and the cells were washed by three cycles of centrifugation (300 G, 5 min, 800 µL of culture medium used for each wash).Cells were finally dispersed in culture medium (600 µL) containing or not Gem (final concentration 0 µM or 0.1 µM) and were maintained in a humid atmosphere at 37 °C with 5% CO2 for 4 days. The number of live cells was determined by cell counting in the presence of trypan blue 1 / 1 (v / v) (triplicate). The experiment was repeated three times independently. Cell viability was expressed as the ratio of the number of live cells after treatment to the number of live cells without any treatment (without irradiation, in the absence of Gem and . cis -GdAzo). A similar procedure was used for the control experiment without irradiation except that the 48-well microplate was not irradiated with gamma rays. A similar procedure was used for the control experiment with Dotarem ®< ( Figure 2f ) except that Dotarem ®< was used instead of cis-GdAzo. The compound cis- GdAzo was obtained by UV irradiation (365 nm, 0.817 mW.cm -2< , 30 min) of the compound trans -GdAzo (105 µL, 500 µM, 1 mM or 1.7 mM, cis -GdAzo > 85%) in a 96-well microplate.
[0159] These results demonstrate: (i) a new concept of activation of therapeutic molecules by the use of ionizing radiation (X-rays, gamma rays, electrons) ( Fig. 1a-f). Since these rays have a very high penetration power in living tissues, this new activation concept therefore has a strong potential for clinical use. All organic molecules described today in the literature require the use of UV to near-IR radiation, rays which do not penetrate biological tissues in depth (they penetrate to a few hundred micrometers in the best conditions). (ii) that it is possible to activate MAzo compounds (M=Cu, Ga, Y, In, Eu, Gd, Yb, Bi) by ionizing radiation with different efficiencies depending on the metal and the irradiation source used ( Fig. 1a-c,f ). The compound GdFAzo can also be activated by ionizing radiation ( Fig. 1c-e ). This compound is characterized by a thermal relaxation slow enough to consider its study in vivo.Although the activation of the GdFAzo compound is relatively low under the experimental conditions used in vitro (compared to the GdAzo compound, Fig. 1c ), it is difficult to predict the molecular activation efficiency that the compound would have in vivo. (iii) the type of metal that must be used to enable the activation of the organic motif. It has been shown that the atomic number Z of the metal must be greater than 39 (that of Yttrium) to allow a significant activation (> 30% under 5 Gy). Indeed, 6 compounds containing a metal of size greater than or equal to that of Yttrium showed such activation while 2 compounds containing metals of smaller sizes (Cu, Z=29, and Ga, Z=31) showed a weak activation (< 10% under 5 Gy) ( Fig. 1f). (iv) that molecular activation can be carried out under various types of ionizing radiation (X-rays, gamma rays, electrons), with different particles (photons and electrons) and various energies (from 1 keV to 4.5 MeV) ( Fig. 1c ), and therefore that all radiotherapy devices currently used in the clinic should be effective in generating the molecular activation described. (v) that the GdAzo compound can induce permeabilization of cancer cell membranes under low-dose ionizing radiation (6.9% (vs 1.2% without irradiation), 8.2% (vs 2.8% without irradiation) and 12.4% (vs 7.5% without irradiation) at GdAzo concentrations of 250 µM, 500 µM and 850 µM respectively by gamma rays at 2 Gy) ( Fig. 2a,b,c ). (vi) that the GdAzo compound can induce toxicity on a gemcitabine-resistant cancer cell line (human acute lymphoblastic leukemia), in the absence or presence of gemcitabine ( Fig. 2d,e), after treatment with gamma rays at 2 Gy. In the absence of gemcitabine, cell viability 4 days after treatment is reduced to 23% ( vs 79% without irradiation), 18% ( vs 42% without irradiation) and 3.0% (vs. 27% without irradiation) at GdAzo concentrations of 250 µM, 500 µM and 850 µM respectively. In the presence of gemcitabine, cell viability 4 days after treatment is reduced to 15% (vs. 49% without irradiation), 9.1% (vs. 30% without irradiation) and 1.2% (vs. 16% without irradiation) at GdAzo concentrations of 250 µM, 500 µM and 850 µM respectively. This study demonstrates that the compound is active alone under ionizing radiation and that the presence of a surrounding active substance only slightly enhances the therapeutic effect of the compound ( Fig. 2d,e). (vii) that the presence of the azobenzene or stillbene motif on the molecule is necessary to generate the therapeutic effect since the commercial control compound Dotarem ®< (gadolinium chelate alone) has no therapeutic effect under ionizing radiation ( Fig. 2f ).
Claims
1. A compound of formula (I): In which: M represents a metal atom selected from Ce(III), Pr(III), Nd(III), Sm(III), Eu(III), Gd(III), Tb(III), Dy(III), Ho(III), Er(III), Tm(III), Yb(III), Mg(II), Ca(II), Mn(II), Fe(II), Fe(III), Cu(II), Zn(II), Ga(III), Y(III), Zr(III), Tc(IV), Tc (VI), Tc (VII), Ru(II), Ru(III), Ru(IV), Pd(II), Ag(I), In(III), Hf (IV), Re(VI), W(II), W(III), W(IV), W(V), W(VI), Os(III), Os(IV), Ir(III), Ir (IV), Pt(II), Au(I), Au (III), TI(III), Zr(IV), Nb(III), Bi(III); n is 1, 2, 3, 4, 5, 6, or 7; V and V', which may be identical or different, are hydrogen atoms or linear or branched C1-C10 alkyl or alkoxy chains, or C1-C10 alkyl chains linked together and comprising one or more heteroatoms selected from N, O, or S, optionally substituted with one or more substituents independently selected from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups, to form a ring; R1, R1', R2, R2', which may be identical or different, are hydrogen atoms, or linear or branched C1-C10 alkyl or alkoxy chains optionally substituted with one or more substituents independently selected from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups; R3 and R3', which may be identical or different, are hydrogen atoms or linear or branched C1-C10 alkyl or alkoxy chains optionally substituted with one or more substituents independently selected from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups, or R3 and R3' are linked together to form a 5- to 14-membered heterocycle or heteroaryl; m and m', which may be identical or different, are equal to 1 or 2; X, X', X", X‴, Y, Y', Y", Y‴, which may be identical or different, are independently selected from H; halogen atoms; alkoxy, alkyl or cycloalkyl groups optionally interrupted or substituted with one or more heteroatom(s) or group(s) COOH, CONH2, COSH, OH, NH2, SH; 5- to 12-membered aryl or heteroaryl groups optionally substituted with one or more COOH, CONH2, COSH groups; COOH or NH2 groups; Z represents an alkyl group optionally interrupted or substituted with one or more heteroatom(s) or a COOH, CONH2, COSH, OH, NH2, SH group; a 5- to 12-membered aryl or heteroaryl group optionally substituted with one or more COOH, CONH2, COSH groups; or a COOH or NH2 group; W and W, which may be the same or different, independently represent a CH2 group; or an aryl or cycloalkyl group; an oxygen or nitrogen atom (secondary or ternary); an amide linkage; an ester linkage; a thioether linkage; U and U', which may be the same or different, represent the CH or NH group, it being understood that the double bond U=U' is in cis or trans form; T represents a CH2 group; a -C(=O)NH group; an alkoxy, alkyl or cycloalkyl group optionally interrupted or substituted with one or more heteroatom(s) or a COOH, CONH2, COSH, OH, NH2, SH group; a 5- to 12-membered aryl or heteroaryl group containing one or more heteroatom(s) and / or optionally substituted with one or more groups chosen from COOalkyl, CONHalkyl, COSHalkyl; R represents H, or linear or branched C1-C18 alkyl or alkoxy chain, optionally substituted with one or more substituents independently selected from halogen atoms, and nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups; p and q are integers between 0 and 6, in particular between 1 and 6; It being understood that in order to ensure the neutrality of the molecule, the n cationic charges of M can be neutralized by 0 to n carboxylate groups (-COOH) optionally substituted on R1, R1', R2, R2', R3, R3', V, V', and / or by 0 to n of the counterions present in solution if necessary; In the form of cis and / or trans isomers and mixtures thereof.
2. A compound of formula (I) according to claim 1, as having the formula (IA): In which: M, n, R1, R2, R3, V, m, R1', R2', R3', V', m', p are defined as in formula (I) and X is selected from hydrogen and halogen atoms; R is a linear or branched C1-C12 alkyl group; The N=N double bond is in cis or trans form; It being understood that in order to ensure the neutrality of the molecule, the n cationic charges of M can be neutralized by 0 to n carboxylate groups (-COOH) substituted on R1, R1', R2, R2', R3, R3', V, V', and / or by 0 to n of the counterions present in solution if necessary.
3. A compound according to claim 1 or 2 having the general formula (IB): in which M, n, p, X and R are defined as in claim 1 or 2.
4. A compound according to any of the preceding claims as having the general formula (IC): in which M, n, X are defined as in the preceding claims.
5. A method for preparing a compound according to any of the preceding claims comprising: - the step of complexing the compound of formula (II): In which: R1, R2, R3, V, m, R1', R2', R3', V', m', Z, T, q, p, W, W, X, X', X", X'", Y, Y', Y", Y‴, R, U, U' are as defined in claim 1 to 4. In the form of cis and / or trans isomers and mixtures thereof; with a precursor of the metal M, and - the possible UV irradiation of the product obtained, in order to predominantly obtain the cis isomer.
6. A method according to claim 5 such that the compound of formula (II) is obtained by coupling a compound of formula (III) and a compound of formula (IV): In which: R1, R2, R3, V, m, R1', R2', R3', V', m', Z, T, q, p, W, W, X, X', X", X'", Y, Y', Y", Y‴, R, U, U' are as defined in claim 1 to 4; and E is a straight or branched C1-C10 alkyl or alkoxy chain, a cycloalkyl or aryl group, optionally comprising one or more heteroatoms selected from N, O or S, optionally integrating or substituted with one or more substituents independently selected from halogen atoms, and anhydride, carboxy, nitrile, nitro, thio, amino, amido, aryl, heteroaryl, hydroxyl, ester, carboxylic acid or carboxylate groups provided that E contains a nucleophilic substituent such as a hydroxyl, thiol or primary or secondary amine function to effect the coupling to the molecule (III); G is a straight or branched C1-C10 alkyl or alkoxy chain, a cycloalkyl or aryl group, optionally comprising one or more heteroatoms selected from N, O or S, optionally substituted with one or more substituents independently selected from halogen atoms, and anhydride, carboxy, nitrile, nitro, thio, amino (primary or secondary), amido, aryl, heteroaryl, hydroxyl, carboxylic acid or carboxylate groups, it being understood that G contains an electrophilic substituent such as an activated carboxylic acid function or an anhydride function in order to carry out the coupling to the molecule (IV).
7. A pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 4 predominantly in cis form, and at least one pharmaceutically acceptable excipient.
8. A compound of formula (I) as defined in any of claims 1 to 4 for use in the treatment of cancer such as lung cancer, pancreatic cancer, liver cancer, spleen cancer, small cell lung carcinoma, prostate cancer, rhabdomyosarcoma, stomach cancer, gastrointestinal cancer, colorectal cancer, kidney cancer, breast cancer, ovarian cancer, testicular cancer, thyroid cancer, head and neck cancer, skin cancer, soft tissue sarcoma, bladder carcinoma, bone cancers, myeloma, plasmacytoma, germ cell cancer, uterine cancer, leukemia, lymphoma, neuroblastoma, osteosarcoma, retinoblastoma, central nervous system cancers, Wilms' tumors.
9. A compound of formula (I) for use according to claim 8, comprising administration of compound (I) mainly in cis form and irradiation of the tumor with ionizing radiation, such as those chosen in particular from X-rays, gamma rays, electron and hadron beams, such as protons or carbon ions.
10. A compound of formula (I) for use according to any of claims 8 to 9 further comprising monitoring said treatment by in vivo medical imaging such as MRI, PET, X-ray or SPECT.
11. A compound of formula (I) for use according to any of claims 8 to 10 further comprising administering one or more anti-cancer agents, such as chemotherapy or immunotherapy such as immune checkpoint inhibitors such as anti-CTLA4, anti-PD-L1 and anti-PD1.
